Business context and reporting period
This is Proteon Therapeutics, Inc.’s audited Form 10-K for the fiscal year ended December 31, 2015, filed March 14, 2016. The request metadata names Protara Therapeutics, Inc.; that does not match the registrant named in the filing. The company was a clinical-stage biopharmaceutical business developing vonapanitase, with no approved products or product-sales revenue.
Vonapanitase was being tested to reduce failure of arteriovenous fistulas (AVFs) used for hemodialysis. PATENCY-1 completed enrollment in October 2015, with top-line results expected in December 2016; PATENCY-2 began enrollment in August 2015, with enrollment expected to finish in Q1 2017.
Financial results and liquidity
Amounts below are in millions of dollars unless noted. The company had no meaningful product revenue, operating profit, or positive cash flow; operating margins are not meaningful for this development-stage business.
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $0 | $2.948 |
| Research and development expense | $12.381 | $6.432 |
| General and administrative expense | $8.489 | $4.096 |
| Total operating expenses / operating loss | $20.870 / $(20.870) | $10.528 / $(7.580) |
| Net loss | $(21.377) | $(3.342) |
| Net loss per share, basic and diluted | $(1.30) | $(3.16) |
| Cash used in operating activities | $(17.566) | $(9.990) |
FY 2014 revenue was a one-time $2.948 million recognition following expiration of rights and obligations under a 2009 agreement, not recurring product revenue. FY 2015 net loss included $0.589 million of realized and unrealized losses associated with Swiss-franc forward contracts.
At December 31, 2015, cash, cash equivalents, and available-for-sale investments totaled $65.263 million, down from $83.595 million a year earlier. Working capital was $62.475 million; current liabilities were $4.133 million, and total liabilities were $4.133 million. The balance sheet reported no debt. Management estimated existing resources would fund operations into Q4 2017, but not completion of PATENCY-2. The company reported an accumulated deficit of $131.251 million.
Material changes versus the prior comparable period
- Net loss widened by $18.035 million as operating expenses increased and the prior-year one-time revenue and favorable non-operating items did not recur.
- R&D expense rose $5.949 million, mainly from Phase 3 trial activity, manufacturing pre-validation, and personnel costs. General and administrative expense increased $4.393 million, including higher public-company costs.
- Operating cash use increased by $7.576 million. Financing cash inflow fell to $0.163 million from $88.520 million in 2014, when the company completed its IPO and Series D financing.
- Cash and investments declined $18.332 million. The company reported total stockholders’ equity of $63.405 million, versus $82.460 million at year-end 2014.
Outlook, commentary, risks, and unusual items
- Management expected higher operating losses and R&D costs as clinical development continued. A BLA submission based on PATENCY-1 alone was a possibility only if results were compelling and after discussion with the FDA; the FDA had not assured that one pivotal trial would suffice.
- The Phase 2 trial did not meet its primary endpoint with statistical significance in the overall population. Positive findings in radiocephalic AVFs and analyses excluding central stenoses were non-prespecified; the company cautioned that these results might not be repeated in Phase 3.
- Further financing was expected to be needed. A sales agreement authorized up to $40 million of at-the-market share sales; it had not been used by December 31, 2015, and the registration statement became effective in January 2016. Additional equity financing could dilute shareholders.
- Key risks include Phase 3 efficacy or safety failure, enrollment or regulatory delays, dependence on third-party manufacturers and clinical contractors, reimbursement and commercial adoption uncertainty, and potential patent challenges. Lonza was the sole or primary API supplier; the filing also disclosed an FDA Warning Letter to a finished-product supplier, while noting the FDA said it did not affect the Phase 3 batch.
- The company had $5.713 million notional of Swiss-franc forward contracts outstanding at year-end. They were not designated for hedge accounting, so fair-value changes affected reported earnings.
- Auditors issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not opine on internal-control effectiveness.
Most important facts for investors to verify
- Confirm the registrant identity: this filing is for Proteon Therapeutics, Inc., not Protara Therapeutics, Inc.
- Check PATENCY-1 results against the December 2016 target and PATENCY-2 enrollment progress against the Q1 2017 target, including trial endpoints and safety disclosures.
- Assess the cash runway against actual spending and the cost to complete PATENCY-2; verify whether and on what terms the company raises capital, including ATM share sales.
- Review manufacturing readiness, supplier inspection status, and availability of validated commercial supply.
- Evaluate whether regulatory approval, reimbursement, market adoption, and patent protection assumptions are supported by subsequent filings and events.